Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taspoglutide versus insulin glargine in insulin-naive adults with type 2 diabetes inadequately controlled on metformin and sulphonylurea
2008-001855-23Phase 3Completed
- Sponsor
- Roche
- Start
- Aug 2008
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of taspoglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Roche. Primary endpoint: Glycemic control assessed by HbA1c at 24 weeks. Started Aug 2008; status: completed.
02
Drugs
taspoglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2008-001855-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001855-23.